• Quizartinib (AC220): Precision FLT3 Inhibition in AML Resear

  2026-05-26

  Quizartinib (AC220) empowers researchers with nanomolar potency and high selectivity for dissecting FLT3-driven signaling in acute myeloid leukemia. Its robust performance in cell-based and in vivo models, combined with advanced protocol recommendations, sets a new standard for translational research targeting FLT3.

• A40926: Dalbavancin Precursor Empowering MRSA & Neisseria As

  2026-05-26

  A40926 stands out as a robust dalbavancin precursor and natural glycopeptide antibiotic, offering unmatched performance in both Gram-positive and Neisseria gonorrhoeae research. Its well-characterized mechanism, precise MIC benchmarks, and flexible assay parameters enable reproducible, high-impact workflows for multidrug-resistant pathogen studies.

• Anagliptin (SK-0403): Advanced Workflows for DPP-4 and Vascu

  2026-05-26

  Anagliptin (SK-0403) redefines metabolic and vascular research with its dual action: potent DPP-4 inhibition and direct modulation of Kv channels and SERCA pumps in vascular tissues. This guide delivers actionable protocols, troubleshooting, and cross-domain applications, unlocking reliable, reproducible results for diabetes and cardiovascular studies.

• Prednisone in Applied Research: Optimized Workflows and Trou

  2026-05-25

  Prednisone, a synthetic corticosteroid, enables precise immunosuppression and apoptosis modeling in bench research. Explore stepwise protocols, advanced use-cases, and troubleshooting strategies that leverage APExBIO's high-purity Prednisone for reproducible, publication-ready data.

• Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP: Optimizing

  2026-05-24

  Explore how the Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated antibody enables precision signal amplification in immunoassays. This article uniquely connects molecular immunomodulation insights to secondary antibody selection for advanced research sensitivity.

• Cell Senescence β-Galactosidase Staining Kit: Applied Workfl

  2026-05-23

  The Cell Senescence β-Galactosidase Staining Kit (SKU: K2185) enables precise, artifact-minimized detection of senescent cells for aging and drug discovery research. This guide details real-world experimental workflows, troubleshooting strategies, and innovations that power high-fidelity senescence assays.

• Lipid Scrambling Regulates Ferroptosis and Tumor Immunity

  2026-05-22

  Yang et al. reveal that TMEM16F-mediated lipid scrambling at the plasma membrane suppresses ferroptosis by remodeling phospholipids, protecting against membrane damage. Inhibiting this process sensitizes tumor cells to ferroptotic death and enhances immune-mediated tumor rejection, suggesting a novel therapeutic angle in cancer research.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Unraveling

  2026-05-22

  Explore the JC-1 Mitochondrial Membrane Potential Assay Kit in depth, revealing its vital role in mitochondrial membrane potential assay and the latest immunomodulatory advances. This article uniquely bridges mechanistic insights with practical assay guidance for advanced research.

• Structural Insights into TRPM3 Modulation by Neurosteroids a

  2026-05-21

  Yin et al. provide a high-resolution structural analysis of the TRPM3 ion channel, revealing how neurosteroids and the anticonvulsant primidone modulate its gating and contribute to disease mechanisms. These findings clarify TRPM3's roles in sensory transduction, pain, and neurodevelopmental disorders, offering a structural basis for targeted therapeutic development.

• CCR5-Positive Extracellular Vesicles Drive RA Pathogenesis

  2026-05-21

  This study uncovers how CCR5-expressing extracellular vesicles from synovial fibroblasts contribute to joint destruction in rheumatoid arthritis. Targeted blocking of CCR5, including via encapsulated Maraviroc, significantly mitigates inflammation and tissue damage, suggesting new intervention strategies.

• CXCR4-Targeted Imaging and Therapy in Lymphoma: Advances and

  2026-05-20

  This review details how CXCR4-targeted imaging ligands and antagonists are reshaping lymphoma research and clinical management. By integrating molecular imaging with precision therapies, the study highlights how these approaches improve diagnosis, prognostic assessment, and therapeutic response in aggressive lymphomas.

• CDCA5 Loss Induces DNA Damage Response in ccRCC: Functional

  2026-05-20

  This study elucidates the pivotal role of CDCA5 in clear cell renal cell carcinoma (ccRCC), demonstrating that its loss triggers apoptosis via activation of the DNA damage response. The findings highlight CDCA5 as both a potential prognostic biomarker and a therapeutic target in ccRCC, providing mechanistic insights with translational relevance for tumor biology research.

• Crystal Violet Staining Solution: Precision in Nuclear Stain

  2026-05-19

  Crystal Violet Staining Solution provides robust and reproducible nuclear staining across colony formation, migration, and invasion assays. By leveraging its strong nucleic acid affinity and optimized workflow parameters, researchers gain enhanced assay clarity and sensitivity—crucial for studies of drug resistance, virulence, and proliferation.

• Hypoxia and Immunometabolism in Tumor Microenvironment

  2026-05-19

  This review dissects how hypoxia-driven metabolic reprogramming and immune modulation shape the tumor microenvironment, fostering immune evasion and tumor progression. The paper's synthesis of metabolic and immunological mechanisms offers a foundation for targeted therapies and highlights the need for precise redox state analysis in tumor biology.

• Dasatinib (BMS-354825): Bridging Kinase Inhibition and EMT R

  2026-05-18

  This thought-leadership article explores how Dasatinib (BMS-354825) enables next-generation translational research at the intersection of kinase signaling, epithelial-mesenchymal transition (EMT), and cancer stemness. By integrating mechanistic insights from recent multi-omics studies in thymic epithelial tumors (TETs)—notably the SNAI1–PIK3R2/p-EphA2 axis—with strategic protocol guidance, we aim to empower researchers developing new models and therapeutics for kinase-driven malignancies.

454 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page